Immunotherapy in head and neck cancer

1. Krzakowski M, Potemski P, Warzocha K, Wysocki P. Onkologia kliniczna. Tom 2. 3rd ed. Gdańsk: Via Medica; 2015.Search in Google Scholar

2. Economopoulou P, Perisanidis C, Giotakis EI, Psyrri A. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med 2016;4:173-85.10.21037/atm.2016.03.34Search in Google Scholar

3. Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016;1:e89829.10.1172/jci.insight.89829Search in Google Scholar

4. Vigneswaran N, Williams MD. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac Surg Clin North Am 2014;26:123-41.10.1016/j.coms.2014.01.001Search in Google Scholar

5. Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X. New immuno-therapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015;36:587-95.10.1016/j.tips.2015.06.005Search in Google Scholar

6. De Costa A-MA, Young MRI. Immunotherapy for head and neck cancer: advances and deficiencies. Anti-Cancer Drugs 2011;22:674-81.10.1097/CAD.0b013e328340fd18Search in Google Scholar

7. Grzywnowicz M, Giannopoulos K. Znaczenie receptora programowanej śmierci 1 oraz jego ligandów w układzie immunologicznym oraz nowotworach. Acta Haematologica Polonica 2012;43:132-45.10.1016/S0001-5814(12)32008-2Search in Google Scholar

8. Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015;33:3293-304.10.1200/JCO.2015.61.1509458616926351330Search in Google Scholar

9. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA – 4 with ipilimumab (MDX-010). Oncologist 2008;13(Suppl 4):16-25.10.1634/theoncologist.13-S4-1619001147Search in Google Scholar

10. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med 2010;363:711-23.10.1056/NEJMoa1003466354929720525992Search in Google Scholar

11. Argiris A, Gillison M, Ferris RL, Harrington K, Sanchez TK, Baudelet C, et al. A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cel carcinoma of the head and neck – CheckMate 651. Ann Oncol 2016;27(Suppl 6):328-50.10.1093/annonc/mdw376.68Search in Google Scholar

12. Guo L, Zhang H, Chen B. Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J Cancer 2017;8:410-6.10.7150/jca.17144Search in Google Scholar

13. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375:1856-67.10.1056/NEJMoa1602252Search in Google Scholar

14. Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Anti-tumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol 2016;34:3838-45.10.1200/JCO.2016.68.1478Search in Google Scholar

15. Cohen EE, Harrington KJ, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Abstract LBA45_PR „Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial”. Zaprezentowano przez Cohen EE. ESMO 2017 Congress, Lugano-Madryt.10.1093/annonc/mdx440.040Search in Google Scholar

16. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7.10.1200/JCO.2006.06.7447Search in Google Scholar

17. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.10.1056/NEJMoa0802656Search in Google Scholar

18. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): An open-label, randomised phase 3 trial. Lancet Oncol 2015;16: 583-94.10.1016/S1470-2045(15)70124-5Search in Google Scholar